ZURA vs. CMPX, ABOS, AGEN, IPHA, OPT, INMB, CHRS, IPSC, KOD, and FENC
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Compass Therapeutics (CMPX), Acumen Pharmaceuticals (ABOS), Agenus (AGEN), Innate Pharma (IPHA), Opthea (OPT), INmune Bio (INMB), Coherus BioSciences (CHRS), Century Therapeutics (IPSC), Kodiak Sciences (KOD), and Fennec Pharmaceuticals (FENC). These companies are all part of the "biological products, except diagnostic" industry.
Compass Therapeutics (NASDAQ:CMPX) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, community ranking and risk.
Compass Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 462.50%. Zura Bio has a consensus target price of $18.83, suggesting a potential upside of 213.89%. Given Zura Bio's higher possible upside, equities research analysts plainly believe Compass Therapeutics is more favorable than Zura Bio.
Compass Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.15, suggesting that its stock price is 85% less volatile than the S&P 500.
Zura Bio's return on equity of -28.59% beat Compass Therapeutics' return on equity.
Compass Therapeutics received 13 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 72.73% of users gave Compass Therapeutics an outperform vote.
In the previous week, Compass Therapeutics had 14 more articles in the media than Zura Bio. MarketBeat recorded 20 mentions for Compass Therapeutics and 6 mentions for Zura Bio. Compass Therapeutics' average media sentiment score of 0.94 beat Zura Bio's score of 0.87 indicating that Zura Bio is being referred to more favorably in the news media.
68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 30.0% of Compass Therapeutics shares are owned by company insiders. Comparatively, 15.8% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Compass Therapeutics beats Zura Bio on 9 of the 14 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
